Sample Page

IP-LAD, or IPLAD, also known as IPR-LAD or as 6-isopropyl-6-nor-LSD, is an analogue of lysergic acid diethylamide (LSD) developed by the team of David E. Nichols.[1][2] In studies on mice, it was found to be approximately 40% the potency of LSD, compared to the 60% increase in potency seen with ETH-LAD, 2-fold potency increase of AL-LAD, and roughly equivalent potency of PRO-LAD.[2] It is not a controlled substance in Canada as of 2025.[3]

See also

References

  1. ^ Nichols DE, Oberlender R, McKenna DJ (1991). “Stereochemical Aspects of Hallucinogenesis”. In Watson RR (ed.). Biochemistry and Physiology of Substance Abuse. Vol. 3. Boca Raton, Fla.: CRC Press. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320. TABLE 1 Effects of N-(6)-Alkyl Subtituents on LSD-Like Behavior and Serotonin Receptor Affinity in Rats […]
  2. ^ a b Hoffman AJ, Nichols DE (September 1985). “Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives”. Journal of Medicinal Chemistry. 28 (9): 1252–1255. doi:10.1021/jm00147a022. PMID 4032428.
  3. ^ “Controlled Drugs and Substances Act”. Department of Justice Canada. Retrieved 19 January 2026.